Progressive multifocal leukoencephalopathy and antipsoriatic drugs

International Journal of Dermatology

Volumn 49, Issue 6, 2010, Pages 631-635

  Di Lernia, Vito ^a  

^a Department of Dermatology Arcispedale S Maria Nuova ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NATALIZUMAB; RITUXIMAB; SALAZOSULFAPYRIDINE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

BRAIN DISEASE; CLINICAL FEATURE; CROHN DISEASE; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENCEPHALITIS; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JC VIRUS; MENINGITIS; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; PSORIASIS VULGARIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEPSIS; TREATMENT DURATION; VIRUS INFECTION; VIRUS PATHOGENESIS; IMMUNOLOGY; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; RISK FACTOR;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; PSORIASIS; RISK ASSESSMENT; RISK FACTORS;

EID: 77954195906     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2010.04475.x     Document Type: Review

References (26)

1. Greenlee JE. Progressive Mulifocal Leucoencephalopathy in the era of natalizumab: a review and discussion of implications. Int MS J 2006, 13:100-107.
2. Markovitz RB, Thompson HC, Mueller JF. Incidence of BK virus and JC virus viruria in human immunodeficiency virus-infected and -uninfected subjects. J Infect Dis 1993, 167:13-20.
3. Bartt RE. Multiple sclerosis, natalizumab therapy, and proressive multifocal leukoencephalopathy. Curr Opin Neurol 2006, 19:341-349.
4. Marzocchetti A, Wuthrich C, Tan CS. Rearrangement of the JC virus regulatory region sequence in the bone marrow of a patient with rheumatoid arthritis and progressive multifocal leukoencephalopathy. J Neurovirol 2008, 14:455-458.
5. Gasnault J, Taoufik Y. New trends in progressive multifocal leukoencephalopathy. Rev Neurol 2006, 162:43-56.
6. Engsig FN, Hansen AB, Omland LH. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis 2009, 199:77-83.
7. Shitrit D, Lev N, Bar-Gil-Shitrit A, Kramer MR. Progressive multifocal leukoencephalopathy in transplant recipients. Transpl Int 2005, 17:658-665.
8. Neff RT, Hurst FP, Falta EM. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 2008, 86:1474-1478.
9. Wang M, Tsai RT, Ou WC. Treatment with cytotoxic immunosuppression agents increases urinary excretion of JCV in patients with autoimmune disease. J Med Virol 2000, 62:505-510.
10. Calabrese LH, Molloy ES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risk of biological immunosuppressive therapies. Ann Rheum Dis 2008, 67(Suppl. 3):iii64-iii65.
11. Warnatz K, Peter HH, Schumacher M. Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature. Ann Rheum Dis 2003, 62:50-57.
12. Boren EJ, Cheema GS, Naguwa SM. The emergence of progressive multifocal leucoencephalopathy (PML) in rheumatic diseases. J Autoimmun 2008, 30:90-98.
13. Rahmlow M, Shuster EA, Dominik J. Leflunomide-associated progressive multifocal leukoencephalopathy. Arch Neurol 2008, 65:1538-1539.
14. Molloy ES, Calabrese LH. Targeted but not trouble free: efalizumab and PML. Nat Rev Rheumatol 2009, 5:418-419.
15. Harris E. Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab. Rheumatology 2008, 47:224-225.
16. Yamamoto M, Takahashi H, Wakasugi H. Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis. Mod Rheumatol 2007, 17:72-74.
17. Roos JC, Ostor AJ. Anti-tumor necrosis factor alpha therapy and the risk of JC virus infection. Arthritis Rheum 2006, 54:381-382.
18. Mohan N, Edwards ET, Cupps TR. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001, 44:2862-2869.
19. Wachi K, Prasertsuntarasai T, Kishimoto M, Uramoto K. T-cell lymphopenia associated with infliximab and cyclophosphamide. Am J Med Sci 2005, 330:48-51.
20. Guttman-Yassky E, Vugmeyster Y, Lowes MA. Blockade of CD11a by efalizumab in psoriasis induces a unique state of T-cell hyporesponsiveness. J Invest Dermatol 2008, 128:1182-1191.
21. Lobb RR, Hemler ME. The pathophysiologic role of alfa4 integrins in vivo. J Clin Invest 1994, 94:1722-1728.
22. Korman BD, Tyler KL, Korman NJ. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression. A cautionary tale for dermatologists. Arch Dermatol 2009, 145:937-942.
23. Ransohoff RM. Natalizumab and PML. Nat Neurosci 2005, 8:1275.
24. Cotone C, Lucentini M, Garcia G, Anibal Molina H. Psoriasis and progressive multifocal leukoencephalopathy in AIDS. Rev Clin Esp 1992, 191:285-286.
25. Berger JR. Progressive multifocal leukoencephalopathy. Curr Treat Options Neurol 2000, 2:361-368.
26. Nijsten T, Spuls P, Naldi L, Stern R. The misperception thata clinical data reflect long-term drug safety. Lessons learned from Efalizumab's withdrawal. Arch Dermatol 2009, 145:1037-1039.